The Food and Drug Administration is tightening enforcement against illegal peptide sales even as it explores broader access through regulated channels, highlighting a growing divide in how these products are handled in the United States.
In August 2026, the agency issued warning letters to four companies accused of marketing unapproved peptide drugs directly to consumers, signaling that despite ongoing policy discussions, enforcement remains strict.
FDA targets direct-to-consumer peptide sellers
The warning letters were sent to:
- Royal Peptides LLC
- Peptide Partners LLC
- NuScience Peptides LLC
- Peak Performance Peptides
According to the FDA, these companies promoted peptides such as semaglutide, tirzepatide and retatrutide with claims related to weight loss, metabolism, sexual function and disease treatment. These claims effectively positioned the products as drugs — without proper approval under the Federal Food Drug and Cosmetic Act.
The agency’s message was clear: selling peptides with medical claims, without approval, is illegal.
“Research use only” is not a loophole
Many peptide sellers attempt to avoid regulation by labeling products as “for research use only.” The FDA rejected that defense.
Instead, regulators focused on real-world signals of intent, including:
- Website claims describing health benefits
- Sale of bacteriostatic water for injections
- Dosing guides and peptide calculators
These elements, taken together, showed that the products were intended for human use — regardless of disclaimers.
Injectables raise the stakes
The FDA placed particular emphasis on injectable peptides, noting they pose higher risks because they bypass the body’s natural defenses.
This includes:
- Risk of contamination
- Incorrect dosing
- Unknown ingredients
As a result, injectable peptide products are facing heightened scrutiny and faster enforcement action.
A two-track regulatory strategy
At the same time, the FDA is not shutting the door entirely on peptides.
Through the Pharmacy Compounding Advisory Committee, the agency is considering allowing certain peptides to be used by licensed compounding pharmacies under Section 503A rules.
Peptides under discussion include:
- BPC-157
- TB-500
- Epitalon
- MOTS-c
- Semax
However, none of the peptides cited in the warning letters are currently approved or under active review for legal marketing.
This creates a dual-track system:
- Track 1: Limited access through regulated compounding channels
- Track 2: Strict enforcement against unapproved online sales
Why this matters
The peptide market has grown rapidly online, driven by fitness trends, anti-aging claims and social media promotion. But regulators are increasingly concerned about:
- Misleading health claims
- Lack of clinical evidence
- Unsafe self-administration
The FDA’s latest actions suggest it is trying to bring order to a fast-growing gray market, rather than ban peptides entirely.
What companies should take away
For businesses operating in the peptide space, the compliance risks are rising.
Key lessons from the enforcement wave:
- Marketing claims alone can trigger legal action
- Website content is treated as product labeling
- Selling injection supplies alongside peptides signals drug intent
- State-level rules may be stricter than federal guidance
Until formal approvals are in place, most peptide products marketed for therapeutic use will continue to be treated as unapproved drugs.